To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe
Read every real review on Google or Yelp
Is the medication branded or compounded
GLP-1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Zepbound, initially developed for diabetes management, show promising potential in treating psoriasis and psoriatic arthritis (PsA)
Structural ensembles data that support the findings of this study are openly available for download on Zenodo at reference number [72]
What are the Potential Effects of Retatrutide Peptides
